Genetic signature of adult gliomas and correlation with MRI features

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In recent years the amount of information concerning the genetics and the biology of gliomas, and particularly of glioblastoma multiforme, increased steadily. Such an increase has been paralleled by the technological progress of MRI. The merging of these scientific areas, as summarized in this review, is helping the stratification of glioma patients for clinical trials and their clinical follow-up. Although available therapeutic options appear limited in number, it is likely that in the next 5 years, both as a consequence of the increased knowledge due to genomic sequencing of hundreds of glioblastoma specimens and to continuous improvements of MRI, new perspectives will be available for these patients, with a sizable impact on their prognosis.

Original languageEnglish
Pages (from-to)709-720
Number of pages12
JournalExpert Review of Molecular Diagnostics
Volume9
Issue number7
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Glioblastoma
Glioma
Clinical Trials
Therapeutics

Keywords

  • EGF receptor amplification
  • Genetic marker
  • Glioma
  • Loss of heterozygosity
  • Methylation
  • MRI
  • Mutation
  • Prognosis

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Pathology and Forensic Medicine

Cite this

@article{2d053e545f0f491b8d6f489622efb96e,
title = "Genetic signature of adult gliomas and correlation with MRI features",
abstract = "In recent years the amount of information concerning the genetics and the biology of gliomas, and particularly of glioblastoma multiforme, increased steadily. Such an increase has been paralleled by the technological progress of MRI. The merging of these scientific areas, as summarized in this review, is helping the stratification of glioma patients for clinical trials and their clinical follow-up. Although available therapeutic options appear limited in number, it is likely that in the next 5 years, both as a consequence of the increased knowledge due to genomic sequencing of hundreds of glioblastoma specimens and to continuous improvements of MRI, new perspectives will be available for these patients, with a sizable impact on their prognosis.",
keywords = "EGF receptor amplification, Genetic marker, Glioma, Loss of heterozygosity, Methylation, MRI, Mutation, Prognosis",
author = "Bruzzone, {Maria Grazia} and Marica Eoli and Valeria Cuccarini and Marina Grisoli and Lorella Valletta and Gaetano Finocchiaro",
year = "2009",
month = "10",
doi = "10.1586/erm.09.44",
language = "English",
volume = "9",
pages = "709--720",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Genetic signature of adult gliomas and correlation with MRI features

AU - Bruzzone, Maria Grazia

AU - Eoli, Marica

AU - Cuccarini, Valeria

AU - Grisoli, Marina

AU - Valletta, Lorella

AU - Finocchiaro, Gaetano

PY - 2009/10

Y1 - 2009/10

N2 - In recent years the amount of information concerning the genetics and the biology of gliomas, and particularly of glioblastoma multiforme, increased steadily. Such an increase has been paralleled by the technological progress of MRI. The merging of these scientific areas, as summarized in this review, is helping the stratification of glioma patients for clinical trials and their clinical follow-up. Although available therapeutic options appear limited in number, it is likely that in the next 5 years, both as a consequence of the increased knowledge due to genomic sequencing of hundreds of glioblastoma specimens and to continuous improvements of MRI, new perspectives will be available for these patients, with a sizable impact on their prognosis.

AB - In recent years the amount of information concerning the genetics and the biology of gliomas, and particularly of glioblastoma multiforme, increased steadily. Such an increase has been paralleled by the technological progress of MRI. The merging of these scientific areas, as summarized in this review, is helping the stratification of glioma patients for clinical trials and their clinical follow-up. Although available therapeutic options appear limited in number, it is likely that in the next 5 years, both as a consequence of the increased knowledge due to genomic sequencing of hundreds of glioblastoma specimens and to continuous improvements of MRI, new perspectives will be available for these patients, with a sizable impact on their prognosis.

KW - EGF receptor amplification

KW - Genetic marker

KW - Glioma

KW - Loss of heterozygosity

KW - Methylation

KW - MRI

KW - Mutation

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=70350049243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350049243&partnerID=8YFLogxK

U2 - 10.1586/erm.09.44

DO - 10.1586/erm.09.44

M3 - Article

VL - 9

SP - 709

EP - 720

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 7

ER -